• Karolinska Development announced an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate (July 2025).
• The portfolio company Modus Therapeutics completed patient enrollment on schedule to the part 1 of its ongoing clinical phase 2a study with sevuparin, which is being evaluated as a treatment for patients with chronic kidney disease with anemia (July 2025).
• The portfolio company Umecrine Cognition raised SEK 24.6 million through a convertible loan to be used for the ongoing clinical phase 1b/2a study of golexanolone in Primary biliary cholangitis (PBC). The convertible loan with attached share options is directed to a consortium of existing long-term shareholders and investors in Umecrine Cognition, including Karolinska Development (July 2025).
• The portfolio company Modus Therapeutics raised SEK 28.3 million in a unit issue with a subscription rate of 189 percent. The proceeds from the rights issue are intended to finance the continued development of the drug candidate, sevuparin, for the treatment of chronic kidney disease (August 2025).
• The portfolio company Umecrine Cognition presented data showing that its drug candidate golexanolone provides sustained reversal of neuroinflammation in a Parkinson's disease model. The data, published in the scientific journal Frontiers in Immunology, support a key mechanism for golexanolone in alleviating symptoms of Parkinson’s disease, which paves the way for the use of golexanolone as a chronic treatment (September 2025).
• The portfolio company AnaCardio completed enrollment in the phase 2a part of its clinical study GOAL-HF1. The ongoing study evaluates AnaCardio’s drug candidate AC01 in patients with heart failure and reduced ejection fraction, with results expected by the end of the year (September 2025). 

Karolinska Development in Penserpoddens podcast Life Science-theme with exciting company pitches- 31 August 2023 (In Swedish)

Karolinska Development - Presentation Erik Penser Bank - 26 augusti 2021 (Video in Swedish)

OssDsign hissar flaggan i frankrike (In Swedish)

Tunga FDA-skalpar för Karolinska Developments portföljbolag Aprea (In Swedish)

Aprea uppnår positiva resultat mot svårfångad målmolekyl (In Swedish)

Karolinska Development-bolaget Forendo Pharma meddelar positiva fas Ia-resultat (In Swedish)

Karolinska Developments portföljbolag Umecrine Cognition levererade positiva säkerhetsdata från fas IIa-studie (In Swedish)